Lunit held its 12th regular shareholder meeting at the Campco Yangjae Tower in Gangnam, Seoul, and announced on the 27th that it passed a total of seven agendas, including the appointment of independent director Lee Jun-pyo, as originally proposed.
On this day, major agenda items, including the new appointment of independent director and audit committee member Lee Jun-pyo, the concurrent role of Garheng Kong, founder of HealthQuest Capital, as an independent director, the approval of the financial statements for the 12th term, and the approval of the limit on director compensation, were all passed.
CEO Seo Beom-seok of Lunit said, “The global investment capability of independent director Lee Jun-pyo and his insights into the AI industry will provide a solid foundation for Lunit's strategy to enter the global market.”
Lunit set its sales target for this year at 80 billion won, which is an increase of about 47% compared to the previous year's sales.
CEO Seo noted, “We are currently conducting simultaneous research discussions with more than 20 leading global pharmaceutical companies in the field of cancer,” adding, “Once the phase one studies advance to phase two, we expect revenue to be generated.” He stated, “We will lead the global medical AI industry through the balanced growth of 'Lunit Insight,' which is continuing stable sales growth, and 'Lunit Scope,' which is poised for collaboration with global big pharma.”